Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,160Revenue $M54.8Net Margin (%)-142.9Z-Score1.9
Enterprise Value $M1,062EPS $-0.7Operating Margin %-135.9F-Score3
P/E(ttm))0Cash Flow Per Share $-0.2Pre-tax Margin (%)-142.9Higher ROA y-yN
Price/Book21.010-y EBITDA Growth Rate %8.2Quick Ratio5.3Cash flow > EarningsY
Price/Sales18.55-y EBITDA Growth Rate %-0.6Current Ratio5.5Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-60.2Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)2ROE % (ttm)-383.3Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M125ROI % (ttm)-92.5Gross Margin Increase y-yN

Gurus Latest Trades with HALO

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
HALOJean-Marie Eveillard 2014-06-30 Add0.03%$7.09 - $12.31
($8.46)
$ 8.946%Add 94.94%2,795,080
HALOKen Fisher 2014-06-30 Buy 0.02%$7.09 - $12.31
($8.46)
$ 8.946%New holding, 791760 sh.791,760
HALOJohn Burbank 2014-06-30 Add$7.09 - $12.31
($8.46)
$ 8.946%Add 55.47%24,523
HALOJohn Burbank 2014-03-31 Buy 0.01%$12.11 - $17.57
($14.89)
$ 8.94-40%New holding, 15773 sh.15,773
HALOJean-Marie Eveillard 2013-12-31 Buy 0.05%$9.66 - $15.7
($12.86)
$ 8.94-30%New holding, 1294580 sh.1,294,580
HALOJohn Burbank 2012-12-31 Sold Out -0.17%$4.82 - $7.07
($5.83)
$ 8.9453%Sold Out0
HALOJohn Burbank 2012-09-30 Add0.07%$4.28 - $9.78
($7.29)
$ 8.9423%Add 66.67%500,000
HALOJohn Burbank 2012-06-30 Add0.03%$7.32 - $13
($8.75)
$ 8.942%Add 50%300,000
HALOJohn Burbank 2012-03-31 Buy 0.09%$9.22 - $13.35
($10.53)
$ 8.94-15%New holding, 200000 sh.200,000
HALOGeorge Soros 2011-12-31 Sold Out -0.0018%$5.72 - $9.73
($8.21)
$ 8.949%Sold Out0
HALOGeorge Soros 2011-09-30 Buy $5.62 - $7.29
($6.61)
$ 8.9435%New holding, 17100 sh.17,100
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

HALO is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
HALO Ken Fisher 2014-06-30791,7600.630.02New Buy
HALO Jean-Marie Eveillard 2014-06-302,795,0802.230.07+94.94%
HALO John Burbank 2014-06-3024,5230.020+55.47%
Premium Most recent portfolio changes are included for Premium Members only!


HALO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Torley HelenPresident and CEO 2014-09-16Buy50,000$8.923.81view
RAMSAY DAVID AVP and CFO 2014-09-16Buy25,000$8.94.04view
PATTON JOHN STUARTDirector 2014-08-19Sell75,000$9.96-7.03view
Engler RobertDirector 2014-08-14Sell35,000$9.96-7.03view
Engler RobertDirector 2014-05-15Sell126,700$7.5622.49view
PATTON JOHN STUARTDirector 2013-09-16Sell75,000$9.131.42view
Shepard H. MichaelVP, Chief Scientific Officer 2013-08-19Sell10,000$7.1130.24view
FALBERG KATHRYN EDirector 2013-08-14Buy100,000$6.8235.78view
Engler RobertDirector 2012-11-29Buy15,000$5.5766.25view
Shaffer James PVP & Chief Commercial Officer 2012-11-14Buy20,000$5.2277.39view

Press Releases about HALO :

    Quarterly/Annual Reports about HALO:

      News about HALO:

      Articles On GuruFocus.com
      Insider Buys at Halozyme Look to Improve Stock Outlook Sep 18 2014 
      comment on HALO May 12 2013 
      comment on HALO May 12 2013 
      comment on HALO May 12 2013 
      Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Aug 06 2010 
      Halozyme Therapeutics Inc. Reports Operating Results (10-Q) May 07 2010 
      Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Nov 06 2009 
      Halozyme Therapeutics Reports Second Quarter 2009 Financial Results Aug 07 2009 
      Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Aug 07 2009 
      Halozyme to Host Conference Call and Webcast on August 7 to Discuss Second Quarter 2009 Financial Re Jul 31 2009 


      More From Other Websites
      Orexigen (OREX) Shows Strength: Stock Gains 11.1% Oct 22 2014
      Illumina (ILMN) Looks Strong: Stock Gains 9.2% Oct 22 2014
      NewLink Genetics Corp. (NLNK) Jumps: Stock Rises 7.1% Oct 21 2014
      Amicus Reports Additional Positive Data on Fabry Therapy Oct 20 2014
      Halozyme Receives FDA Approval For Additional Manufacturing Facilities For Hylenex® Recombinant Oct 20 2014
      Baxter Launches HYQVIA in the United States for Adult Patients with Primary Immunodeficiency Oct 20 2014
      Baxter Launches HYQVIA in the United States for Adult Patients with Primary Immunodeficiency Oct 20 2014
      Halozyme Receives FDA Approval For Additional Manufacturing Facilities For Hylenex® Recombinant Oct 20 2014
      Regeneron Pharmaceuticals (REGN) Jumps: Stock Up 8.5% Oct 20 2014
      MannKind (MNKD) Worth Watching: Stock Gains 12.9% Oct 16 2014
      Synageva BioPharma (GEVA) Shows Strength: Stock Up 7.4% Oct 16 2014
      Sunesis Pharmaceuticals (SNSS) Jumps: Stock Gains 8.5% Oct 15 2014
      MiMedx Group (MDXG) Worth Watching: Stock Rises 9.7% Oct 15 2014
      Tenax Therapeutics (TENX) Jumps: Stock Moves Up 7.8% Oct 15 2014
      NewLink Genetics (NLNK) Shows Strength: Stock Up 23.7% Oct 14 2014
      Prosensa Holding N.V. (RNA) in Focus: Stock up 8.5% Oct 14 2014
      Halozyme Announces Podium Presentation On PEGPH20 At The New York Academy Of Sciences Oct 09 2014
      Halozyme Announces Issuance Of U.S. Patent For Companion Diagnostic For PEGPH20 Oct 07 2014
      Strong JOBS = Strong MARKETS Oct 03 2014
      Halozyme Receives Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For... Oct 03 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK